Overall, we established a proof of concept that AMG853, a clinically relevant bispecific PTGDR-1 and PTGDR-2 antagonist, can control lupus-like inflammation in a manner similar to the combination of PTGDR-1- and PTGDR-2-specific antagonists. The gene discussed is PTGDR; the disease is systemic lupus erythematosus.